NCT00742144View on ClinicalTrials.gov

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 19, 2008

Primary Completion Date

November 18, 2009

Study Completion Date

November 18, 2009

Conditions
Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular
Interventions
DRUG

ofatumumab

Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.

Trial Locations (3)

466-8650

GSK Investigational Site, Aichi

104-0045

GSK Investigational Site, Tokyo

135-8550

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY